[go: up one dir, main page]

ZA200203797B - Comminuted form of (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy)phenyl] propanoic acid. - Google Patents

Comminuted form of (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy)phenyl] propanoic acid. Download PDF

Info

Publication number
ZA200203797B
ZA200203797B ZA200203797A ZA200203797A ZA200203797B ZA 200203797 B ZA200203797 B ZA 200203797B ZA 200203797 A ZA200203797 A ZA 200203797A ZA 200203797 A ZA200203797 A ZA 200203797A ZA 200203797 B ZA200203797 B ZA 200203797B
Authority
ZA
South Africa
Prior art keywords
substance
composition
prophylaxis
compound according
treatment
Prior art date
Application number
ZA200203797A
Other languages
English (en)
Inventor
Agneta Hallgren
Kristina Roos
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200203797B publication Critical patent/ZA200203797B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200203797A 1999-12-03 2002-05-13 Comminuted form of (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy)phenyl] propanoic acid. ZA200203797B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904413A SE9904413D0 (sv) 1999-12-03 1999-12-03 Comminuted form

Publications (1)

Publication Number Publication Date
ZA200203797B true ZA200203797B (en) 2003-08-13

Family

ID=20417978

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200203797A ZA200203797B (en) 1999-12-03 2002-05-13 Comminuted form of (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy)phenyl] propanoic acid.

Country Status (32)

Country Link
EP (1) EP1237854B1 (xx)
JP (1) JP2003515580A (xx)
KR (1) KR20020067538A (xx)
CN (1) CN1216859C (xx)
AR (1) AR029456A1 (xx)
AT (1) ATE251131T1 (xx)
AU (1) AU766036B2 (xx)
BR (1) BR0016135A (xx)
CA (1) CA2392029A1 (xx)
CO (1) CO5271736A1 (xx)
CZ (1) CZ20021839A3 (xx)
DE (1) DE60005710T2 (xx)
DK (1) DK1237854T3 (xx)
EE (1) EE200200284A (xx)
ES (1) ES2208444T3 (xx)
HK (1) HK1049324B (xx)
HU (1) HUP0203692A3 (xx)
IL (1) IL149516A0 (xx)
IS (1) IS6399A (xx)
MX (1) MXPA02005165A (xx)
MY (1) MY125099A (xx)
NO (1) NO20022591L (xx)
NZ (1) NZ518926A (xx)
PL (1) PL355372A1 (xx)
PT (1) PT1237854E (xx)
RU (1) RU2248966C2 (xx)
SE (1) SE9904413D0 (xx)
SK (1) SK7662002A3 (xx)
TR (1) TR200400003T4 (xx)
UA (1) UA73959C2 (xx)
WO (1) WO2001040169A1 (xx)
ZA (1) ZA200203797B (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
AU749505B2 (en) 1997-10-27 2002-06-27 Dr. Reddy's Laboratories Limited Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
AU752059B2 (en) 1997-10-27 2002-09-05 Dr. Reddy's Laboratories Limited Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
WO1999016758A1 (en) 1997-10-27 1999-04-08 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
JP2002528535A (ja) 1998-10-29 2002-09-03 ドクター・レディーズ・リサーチ・ファウンデーション 新規抗糖尿病剤製造の改良方法
US6531596B1 (en) 1998-10-29 2003-03-11 Dr. Reddy's Laboratories Ltd. Process for the preparation of new antidiabetic agents
US6897199B2 (en) 2001-02-05 2005-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
CA2546601A1 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
EP1586573B1 (en) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
BRPI0716134A2 (pt) 2006-09-07 2013-09-17 Nycomed Gmbh tratamento de combinaÇço para diabetes mellitus
BRPI0808495A2 (pt) 2007-03-08 2014-07-22 Albireo Ab Derivados de ácido 2-substituído-3-fenilpropiônico e seu uso no tratamento de doença inflamatória intestinal
WO2008149345A2 (en) 2007-06-04 2008-12-11 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
CN106061940A (zh) 2013-11-05 2016-10-26 本古里安大学内盖夫研究发展局 治疗糖尿病和由其引发的并发疾病的化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
SE9704873D0 (sv) * 1997-12-23 1997-12-23 Astra Ab Sampling apparatus
MA26634A1 (fr) * 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues

Also Published As

Publication number Publication date
HK1049324B (en) 2004-04-30
NZ518926A (en) 2003-11-28
NO20022591D0 (no) 2002-05-31
DE60005710T2 (de) 2004-08-05
NO20022591L (no) 2002-05-31
MXPA02005165A (es) 2003-09-25
DK1237854T3 (da) 2004-01-12
AU2034801A (en) 2001-06-12
ATE251131T1 (de) 2003-10-15
DE60005710D1 (en) 2003-11-06
KR20020067538A (ko) 2002-08-22
JP2003515580A (ja) 2003-05-07
IL149516A0 (en) 2002-11-10
WO2001040169A1 (en) 2001-06-07
CN1402704A (zh) 2003-03-12
BR0016135A (pt) 2002-08-20
EE200200284A (et) 2003-08-15
HUP0203692A2 (hu) 2003-03-28
CO5271736A1 (es) 2003-04-30
RU2002113169A (ru) 2004-01-20
CZ20021839A3 (cs) 2002-08-14
PL355372A1 (en) 2004-04-19
ES2208444T3 (es) 2004-06-16
IS6399A (is) 2002-05-28
CA2392029A1 (en) 2001-06-07
HK1049324A1 (en) 2003-05-09
EP1237854B1 (en) 2003-10-01
PT1237854E (pt) 2004-02-27
HUP0203692A3 (en) 2005-05-30
EP1237854A1 (en) 2002-09-11
AR029456A1 (es) 2003-07-02
SK7662002A3 (en) 2002-10-08
AU766036B2 (en) 2003-10-09
TR200400003T4 (tr) 2004-02-23
CN1216859C (zh) 2005-08-31
RU2248966C2 (ru) 2005-03-27
MY125099A (en) 2006-07-31
UA73959C2 (en) 2005-10-17
SE9904413D0 (sv) 1999-12-03

Similar Documents

Publication Publication Date Title
EP1237854B1 (en) Comminuted form of (s)-2-ethoxy -3- 4-(2- 4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid
JP5698682B2 (ja) トライアシル−３−ヒドロキシフェニルアデノシン及びその血中脂肪の調節用途
CN108601751A (zh) 雷公藤红素的类似物
TWI718104B (zh) AHU-377結晶型游離酸、半鈣鹽、α-苯乙胺鹽及其製備方法和應用
EP1237855B1 (en) Crystalline form of (s)-2 ethoxy-3- 4-(2- 4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid
US20090176846A1 (en) N-hydroxy-4- {5- [4- (5-isopropyl-2-methyl-1, 3-thiazol-4-yl) phenoxy] pentoxy} benzamidine 2 methanesulfonic acid salt
WO2001040166A1 (en) Comminuted form of 3-{4-[2-(4-tert-butoxycarbonylaminophenyl)ethoxy]phenyl}-(s)-2-ethoxy propanoic
US7084177B2 (en) Comminuted form of(S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl] propanoic acid
CN101993417A (zh) 磷酸二甲啡烷的稳定新晶型
JP5102849B2 (ja) Ｎ−ヒドロキシ−４−｛５−［４−（５−イソプロピル−２−メチル−１，３−チアゾール−４−イル）フェノキシ］ペントキシ｝ベンズアミジン２エタンスルホン酸塩、その製造方法およびそれを含む薬学組成物
CN113214206B (zh) 橙皮素与甜菜碱共晶物b及制备方法和其组合物与用途
US20130116291A1 (en) Association of xanthine oxidase inhibitors and statins and use thereof
WO2005016331A1 (ja) Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤
CN116999447A (zh) 美沙拉嗪与精氨酸的共无定型物及其制备方法和用途
TW202130348A (zh) 艾拉菲諾多形體
EP2266948A1 (en) Salts of tramadol and diflunisal and their crystal form in the treatment of pain
JPWO2001025198A1 (ja) 三環性アミノアルコール誘導体の溶解性改善方法